ELFABRIO®▼ (PEGUNIGALSIDASE ALFA) IMPORTANT INFORMATION on minimising the risk of hypersensitivity reactions and medication errors in home settings Information for Patients, Caregivers and Healthcare Professionals

ELFABRIO®▼ (PEGUNIGALSIDASE ALFA) IMPORTANT INFORMATION: Information for Healthcare Professionals

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material before prescribing Eliquis as it contains important safety information on the important risks of bleeding, and medication errors during treatment with apixaban and their appropriate management.

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Carry Card for EpiPen® patients

Trainer Pen order form

Travel Certificate for those carrying EpiPen®

Guide to Using Your EpiPen® & Trainer EpiPen® leaflet

Checklist for EpiPen and EpiPen Jr

Educational materials for patients on importation safety information card for valproate - Contraception and Pregnancy Prevention

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Healthcare Professional (HCP) educational material on important safety information associated with Valproate use.

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

FOR DISPENSARY USE ONLY Pharmacy poster with key information about the Pregnancy Prevention Programme.

Female Patient Guide on important safety information associated with Valproate use - educational material

Male Patient Guide on important safety information associated with Valproate use - educational material

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)

Your guide to Eylea - for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)

Your guide to Eylea - for the treatment of visual impairment due to diabetic macular oedema (DMO)

Prescriber guide to intravitreal injections with Eylea.

Information for parents and caregivers – for the treatment of retinopathy of prematurity (ROP)

Your guide to Eylea - for the treatment of neovascular (wet) age-related macular degeneration (AMD).